China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
23.7
38.93
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
China Resources Boya Bio pharmaceutical Group Co Ltd
Long-Term Investments
China Resources Boya Bio pharmaceutical Group Co Ltd
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
|
Long-Term Investments
ÂĄ194.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
||
Beigene Ltd
HKEX:6160
|
Long-Term Investments
ÂĄ635.2m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Long-Term Investments
ÂĄ10m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Long-Term Investments
ÂĄ1.4B
|
CAGR 3-Years
89%
|
CAGR 5-Years
126%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Long-Term Investments
ÂĄ17B
|
CAGR 3-Years
8%
|
CAGR 5-Years
117%
|
CAGR 10-Years
N/A
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Long-Term Investments
ÂĄ295.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
24%
|
CAGR 10-Years
39%
|
China Resources Boya Bio pharmaceutical Group Co Ltd
Glance View
Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. The company is headquartered in Fuzhou, Jiangxi and currently employs 1,652 full-time employees. The company went IPO on 2012-03-08. The firm's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The firm's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The firm also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The firm distributes its products mainly in domestic market.
See Also
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Long-Term Investments?
Long-Term Investments
194.9m
CNY
Based on the financial report for Sep 30, 2024, China Resources Boya Bio pharmaceutical Group Co Ltd's Long-Term Investments amounts to 194.9m CNY.
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
11%
Over the last year, the Long-Term Investments growth was 73%. The average annual Long-Term Investments growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been 10% over the past three years , 7% over the past five years , and 11% over the past ten years .